SLGL - Sol-Gel Technologies Ltd.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Sol-Gel Technologies Ltd.

7 Golda Meir Street
Weizmann Science Park
Ness Ziona 7403650
972 8 931 3433

Full-time employees49

Key executives

NameTitlePayExercisedYear born
Dr. Alon Seri-LevyCo-Founder, CEO & Director425N/A1961
Mr. Gilad MamlokChief Financial Officer345N/A1968
Mr. Itzik YosefVP of Operations158N/A1976
Prof. David AvnirCo-FounderN/AN/AN/A
Dr. Karine NeimannVP of Projects & Planning and Chief ChemistN/AN/A1971
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN, which has completed Phase II clinical trials for the treatment of acne vulgaris; and Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.

Corporate governance

Sol-Gel Technologies Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more